E
VBIV

Ergoteles’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Ergoteles’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,139
Closed -$83.8K – 1870
2022
Q4 		$83.8K Buy
7,139
+4,908
+220% +$86.6K ﹤0.01% 1241
2022
Q3 		$47K Sell
2,231
-16,577
-88% -$447K ﹤0.01% 1445
2022
Q2 		$456K Buy
18,808
+11,572
+160% +$394K 0.01% 879
2022
Q1 		$360K Buy
+7,236
New +$358K 0.01% 783
2021
Q4 		– Sell
-5,704
Closed -$532K – 1673
2021
Q3 		$532K Buy
+5,704
New +$542K 0.02% 554
2020
Q4 		– Sell
-1,353
Closed -$116K – 955
2020
Q3 		$116K Buy
+1,353
New +$158K 0.02% 529

Other funds holding VBIV

PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.51B AUM 37.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return